Phase Ib Study of Oral VK-2019 for Adults With Relapsed or Refractory EBV-Positive Diffuse Large B-Cell Lymphoma

What this Trial Is About

This research aims to evaluate VK-2019 in adult patients with relapsed or refractory Epstein-Barr virus EBV-positive diffuse large B-cell lymphoma DLBCL who have previously undergone at least two systemic therapies. The study is a Phase Ib, open-label trial focusing on the safety and tolerability of VK-2019. It includes biomarker assessments to better understand treatment effects in this population with limited standard care options. Participants receive daily oral doses of VK-2019 in one of three dose escalation groups 600 mg, 1200 mg, or 1800 mg per day. Treatment cycles last 28 days and repeat until disease progression or unacceptable side effects occur. Patients who achieve stable disease or better after three cycles may continue therapy. Dose adjustments may be made if toxicity is observed. During the study, participants undergo response assessments every three cycles and are monitored for survival for up to three years. Researchers track safety measures including dose-limiting toxicities and organ function. Participants also complete scheduled laboratory tests and clinical evaluations to assess treatment impact and tolerability throughout the study period.

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)